Bristol-Myers Squibb Co (BMY)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Giovanni Caforio
Employees:
32,200
345 PARK AVE, NEW YORK, NY 10154
2125464000

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma.

Data derived from most recent annual or quarterly report
Market Cap 157.92 Billion Shares Outstanding2.18 Billion Avg 30-day Volume 7.824 Million
P/E Ratio22.5622 Dividend Yield2.9907 EPS1.37
Price to Revenue3.2232 Debt to Equity1.1944 EBITDA18.04 Billion
Price to Book Value4.6111 Operating Margin19.0252 Enterprise Value180.782 Billion
Current Ratio1.416 EPS Growth2.29 Quick Ratio0.985
1 Yr BETA 0.2805 52-week High/Low 80.8 / 61.06 Profit Margin14.3181
Operating Cash Flow Growth-10.8868 Altman Z-Score2.5636 Free Cash Flow to Firm 11.228 Billion
Earnings Report2023-02-02
View SEC Filings from BMY instead.

View recent insider trading info

Funds Holding BMY (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding BMY

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Events (8k)

  • 8-K: filed on 2023-01-09:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-10-26:
    Item 2.02: Results of Operations and Financial Condition
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-07-27:
    Item 2.02: Results of Operations and Financial Condition
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-15:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-04-29:
    Item 2.02: Results of Operations and Financial Condition
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-04-18:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-03-17:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2022-03-03:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-03-02:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 1.01: Entry into a Material Definitive Agreement
    Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-02-24:
    Item 8.01: Other Events
  • Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    20.2 Thousand total shares from 3 transactions

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    STORCH GERALD L

    • Director
    74,040 2022-12-31 5

    YALE PHYLLIS R

    • Director
    16,568 2022-12-31 5

    ARDUINI PETER J

    • Director
    40,486 2022-12-31 5

    RICE DERICA W

    • Director
    12,589 2022-12-31 5

    HALLER JULIA A

    • Director
    16,826 2022-12-31 6

    SAMUELS THEODORE R. II

    • Director
    34,624 2022-12-31 5

    HIDALGO MEDINA MANUEL

    • Director
    5,914 2022-12-31 5

    BHATT DEEPAK

    • Director
    1,991 2022-12-31 5

    ELKINS DAVID V EVP, CHIEF FINANCIAL OFFICER

    • Officer
    133,078 2022-12-02 4

    BOERNER CHRISTOPHER S. EVP, CHIEF COMMERCIAL OFFICER

    • Officer
    45,892 2022-12-02 3

    VESSEY RUPERT EVP, RESEARCH & EARLY DEV.

    • Officer
    70,811 2022-12-02 6

    POWELL ANN EVP, CHIEF HUMAN RESOURCES

    • Officer
    34,226 2022-11-09 3

    CAFORIO GIOVANNI BOARD CHAIR AND CEO

    • Officer
    • Director
    476,104 2022-09-20 6

    HIRAWAT SAMIT EVP,CHIEF MED.OFFR.,DRUG DEV.

    • Officer
    30,649 2022-07-01 2

    WEESE MICHELLE EVP, CORPORATE AFFAIRS

    • Officer
    6,858 2022-07-01 2

    LEUNG SANDRA EVP, GENERAL COUNSEL

    • Officer
    399,083 2022-06-06 2

    GREENLEES SHARON SVP & CONTROLLER

    • Officer
    8,202 2022-05-02 2

    MILY ELIZABETH EVP, STRATEGY & BD

    • Officer
    24,036 2022-04-01 2

    SHANAHAN KARIN EVP, GLOB. PROD. DEV. & SUPPLY

    • Officer
    13,225 2022-04-01 3

    SANTIAGO KAREN MURPHY SVP & CONTROLLER

    • Officer
    16,704 2022-03-14 2

    MEYERS GREGORY SCOTT EVP, CHIEF DIGITAL & TECH OFF.

    • Officer
    28,368 2022-03-10 2

    PRICE PAULA A

    • Director
    8,255 2022-02-01 1

    VOUSDEN KAREN H

    • Director
    21,415 2022-02-01 1

    VON AUTENRIED PAUL EVP, CHIEF INFORMATION OFFICER

    • Officer
    63,536 2021-11-22 0

    DUBOW ADAM SVP,CHIEFCOMPLIANCE&ETHICSOFF.

    • Officer
    14,749 2021-07-30 0

    BONNEY MICHAEL W

    • Director
    9,342 2021-06-30 0

    EID JOSEPH SVP,HEAD GLOB. MEDICAL AFFAIRS

    • Officer
    13,794 2021-06-03 0

    SCHMUKLER LOUIS S EVP,PRES.,GLOB.PROD. & SUPPLY

    • Officer
    31,956 2021-05-10 0

    BERTOLINI ROBERT J

    • Director
    26,648 2021-03-31 0

    EMMENS MATTHEW

    • Director
    26,999 2021-03-31 0

    PALIWAL DINESH C

    • Director
    40,501 2021-03-31 0

    SATO VICKI L

    • Director
    0 2021-02-01 0

    AHMED NADIM EVP AND PRESIDENT, HEMATOLOGY

    • Officer
    40,855 2020-12-31 0

    LACY ALAN J

    • Director
    0 2020-06-30 0

    GROBSTEIN MICHAEL

    • Director
    0 2020-06-30 0

    BANCROFT CHARLES A EVP, HEAD OF INTEGRATION

    • Officer
    437,534 2020-03-10 0

    ELICKER JOHN E EVP, INVESTOR RELATIONS

    • Officer
    70,946 2020-03-10 0

    METCALFE KATHRYN EVP, CORPORATE AFFAIRS

    • Officer
    0 2020-03-10 0

    BIONDI PAUL SVP, HEAD OF STRATEGY & BD

    • Officer
    6,214 2019-10-02 0

    LYNCH THOMAS J. JR. EVP & CHIEF SCIENTIFIC OFFICER

    • Officer
    22,223 2019-04-03 0

    STORCH GERALD L

    STORCH GERALD L

    • Director
    0 2018-09-30 5

    BASELGA JOSE

    • Director
    No longer subject to file 2018-09-30 0

    GORDON MURDO EVP, CHIEF COMMERCIAL OFFICER

    • Officer
    No longer subject to file 2018-08-01 0

    CALDARELLA JOSEPH C SVP & CONTROLLER

    • Officer
    48,076 2017-09-06 0

    NIELSEN ANNE CHIEF COMPLIANCE & ETHICS OFF

    • Officer
    37,974 2017-09-03 0

    ANDREOTTI LAMBERTO

    • Director
    1,176,844 2017-04-06 0

    CUSS FRANCIS M EVP & CSO

    • Officer
    321,906 2017-03-10 0

    BLIN EMMANUEL SVP, CHIEF STRATEGY OFFICER

    • Officer
    20,138 2017-03-10 0

    WEST TOGO D JR

    • Director
    0 2017-02-01 0

    GLIMCHER LAURIE H M.D.

    • Director
    0 2017-02-01 0

    CAMPBELL LEWIS B

    • Director
    2,110 2016-03-08 0

    CORNELIUS JAMES M

    • Director
    79,851 2015-03-31 0

    MOED SAMUEL J SVP, STRAT PLAN & ANALYSIS

    • Officer
    31,615 2015-03-13 0

    DANIELS BRIAN SVP GLOBAL DEV & MED AFFAIRS

    • Officer
    No longer subject to file 2014-07-01 0

    HELLER FRANCES K SVP, BUSINESS DEVELOPMENT

    • Officer
    4,218 2014-03-10 0

    SIGAL ELLIOT EVP, CSO & PRESIDENT R&D

    • Officer
    • Director
    195,300 2013-06-03 0

    CAZALA BEATRICE J EVP COMMERCIAL OPERATIONS

    • Officer
    177,118 2013-05-31 0

    FREEH LOUIS J

    • Director
    0 2013-02-01 0

    WILLIAMS R SANDERS

    • Director
    0 2013-02-01 0

    CELENTANO JOHN E SVP HR PUBLIC AFFAIRS & PHILAN

    • Officer
    142,142 2012-03-06 0

    LEVIN JEREMY M SVP STRAT TRANSACTIONS

    • Officer
    43,689 2011-10-01 0

    CARLO DE NOTARISTEFANI PRES TECH OPS & SUPP FNCTNS

    • Officer
    8,432 2011-06-14 0

    HOOPER ANTHONY C SVP COMOPS PRES USJAP INT

    • Officer
    208,419 2011-05-13 0

    JOHANSSON LEIF

    • Director
    0 2011-02-01 0

    ZITO ROBERT T SVP & CHIEF COMM OFFICER

    • Officer
    35,469 2010-03-06 0

    MCBRIDE ANTHONY A SVP HUMAN RESOURCES

    • Officer
    34,292 2010-03-06 0

    HUET JEAN-MARC EVP & CFO

    • Officer
    25,000 2009-04-30 0

    ROBINSON JAMES D III

    • Director
    0 2007-12-31 0

    BONFIELD ANDREW R J EVP & CFO

    • Officer
    150,206 2007-10-01 0

    BEAR STEPHEN E SVP, HUMAN RESOURCES

    • Officer
    76,257 2007-09-10 0

    COFFMAN VANCE D

    • Director
    44,870 2006-09-29 0

    DOLAN PETER R FORMER CEO

    • Officer
    • Director
    606,946 2006-09-08 0

    BODNAR ANDREW G SVP, STRAT & MED & EXT AFFAIRS

    • Officer
    323,464 2006-09-08 0

    ALLEN ROBERT E

    • Director
    2,500 2006-05-02 0

    GLIMCHER LAURIE H MD

    • Director
    2,500 2006-05-02 0

    SULLIVAN LOUIS W

    • Director
    22,932 2006-03-31 0

    GERSTNER LOUIS V JR

    • Director
    42,402 2006-03-09 0

    MCGOLDRICK JOHN L EXECUTIVE VP

    • Officer
    223,999 2006-03-07 0

    DIXON WENDY L CMO & PRES, GLOBAL MARKETING

    • Officer
    128,868 2006-03-07 0

    HOWSON TAMAR D SVP, CORP & BUS DEVELOPMENT

    • Officer
    112,671 2006-03-07 0

    WILLARD RICHARD K SVP & GENERAL COUNSEL

    • Officer
    203,300 2006-03-07 0

    ZABOR DAVID L VP STRAT BUS INITIATIVES

    • Officer
    104,665 2006-03-07 0

    DWYER EDWARD M VICE PRESIDENT & TREASURER

    • Officer
    41,257 2006-03-07 0

    WOLGEMUTH RICHARD L SVP, GLOBAL REG SCIENCES

    • Officer
    68,936 2006-03-07 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    HALLER JULIA A - Director

    2023-01-04 17:25:30 -0500 2022-12-31 A 469 $71.95 a 16,826 direct

    ARDUINI PETER J - Director

    2023-01-04 17:25:04 -0500 2022-12-31 A 469 $71.95 a 40,486 direct

    HIDALGO MEDINA MANUEL - Director

    2023-01-04 17:24:39 -0500 2022-12-31 A 117 $71.95 a 5,914 direct

    YALE PHYLLIS R - Director

    2023-01-04 17:24:01 -0500 2022-12-31 A 469 $71.95 a 16,568 direct

    SAMUELS THEODORE R. II - Director

    2023-01-04 17:23:32 -0500 2022-12-31 A 678 $71.95 a 34,624 direct

    BHATT DEEPAK - Director

    2023-01-04 17:22:54 -0500 2022-12-31 A 104 $71.95 a 1,991 direct

    STORCH GERALD L - Director

    2023-01-04 17:22:08 -0500 2022-12-31 A 504 $71.95 a 74,040 direct

    RICE DERICA W - Director

    2023-01-04 17:21:35 -0500 2022-12-31 A 504 $71.95 a 12,589 direct

    BOERNER CHRISTOPHER S. - Officer EVP, CHIEF COMMERCIAL OFFICER

    2022-12-06 19:32:20 -0500 2022-12-02 M 2,637 d 2,638 direct

    VESSEY RUPERT - Officer EVP, RESEARCH & EARLY DEV.

    2022-12-06 18:43:56 -0500 2022-12-02 M 8,792 a 65,871 direct -0.0626 -3.4906 -7.6201 0.0 1 -10.4574 22

    BOERNER CHRISTOPHER S. - Officer EVP, CHIEF COMMERCIAL OFFICER

    2022-12-06 19:32:20 -0500 2022-12-02 F 1,349 $81.13 d 43,254 direct -0.0626 -3.4906 -7.6201 0.0 1 -10.4574 22

    BOERNER CHRISTOPHER S. - Officer EVP, CHIEF COMMERCIAL OFFICER

    2022-12-06 19:32:20 -0500 2022-12-02 M 2,637 a 44,603 direct -0.0626 -3.4906 -7.6201 0.0 1 -10.4574 22

    ELKINS DAVID V - Officer EVP, CHIEF FINANCIAL OFFICER

    2022-12-06 18:44:15 -0500 2022-12-02 M 8,792 d 8,792 direct

    ELKINS DAVID V - Officer EVP, CHIEF FINANCIAL OFFICER

    2022-12-06 18:44:15 -0500 2022-12-02 F 4,498 $81.13 d 124,080 direct -0.0626 -3.4906 -7.6201 0.0 1 -10.4574 22

    ELKINS DAVID V - Officer EVP, CHIEF FINANCIAL OFFICER

    2022-12-06 18:44:15 -0500 2022-12-02 M 8,792 a 128,578 direct -0.0626 -3.4906 -7.6201 0.0 1 -10.4574 22

    VESSEY RUPERT - Officer EVP, RESEARCH & EARLY DEV.

    2022-12-06 18:43:56 -0500 2022-12-02 M 8,792 d 8,792 direct

    VESSEY RUPERT - Officer EVP, RESEARCH & EARLY DEV.

    2022-12-06 18:43:56 -0500 2022-12-02 F 4,498 $81.13 d 61,373 direct -0.0626 -3.4906 -7.6201 0.0 1 -10.4574 22

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    BRISTOL-MYERS SQUIBB CO BMY 2023-01-27 22:15:03 UTC 4.07 0.25 0
    BRISTOL-MYERS SQUIBB CO BMY 2023-01-27 21:45:04 UTC 4.07 0.25 0
    BRISTOL-MYERS SQUIBB CO BMY 2023-01-27 21:15:04 UTC 4.07 0.25 0
    BRISTOL-MYERS SQUIBB CO BMY 2023-01-27 20:45:03 UTC 4.07 0.25 0
    BRISTOL-MYERS SQUIBB CO BMY 2023-01-27 20:15:04 UTC 4.07 0.25 0
    BRISTOL-MYERS SQUIBB CO BMY 2023-01-27 19:45:03 UTC 4.07 0.25 0
    BRISTOL-MYERS SQUIBB CO BMY 2023-01-27 19:15:03 UTC 4.07 0.25 0
    BRISTOL-MYERS SQUIBB CO BMY 2023-01-27 18:45:04 UTC 4.07 0.25 0
    BRISTOL-MYERS SQUIBB CO BMY 2023-01-27 18:15:03 UTC 4.07 0.25 0
    BRISTOL-MYERS SQUIBB CO BMY 2023-01-27 17:45:03 UTC 4.07 0.25 0
    BRISTOL-MYERS SQUIBB CO BMY 2023-01-27 17:15:04 UTC 4.07 0.25 0
    BRISTOL-MYERS SQUIBB CO BMY 2023-01-27 16:45:03 UTC 4.07 0.25 0
    BRISTOL-MYERS SQUIBB CO BMY 2023-01-27 16:15:03 UTC 4.07 0.25 0
    BRISTOL-MYERS SQUIBB CO BMY 2023-01-27 15:45:03 UTC 4.07 0.25 0
    BRISTOL-MYERS SQUIBB CO BMY 2023-01-27 15:15:04 UTC 4.07 0.25 0
    BRISTOL-MYERS SQUIBB CO BMY 2023-01-27 14:45:04 UTC 4.07 0.25 0
    BRISTOL-MYERS SQUIBB CO BMY 2023-01-27 14:15:03 UTC 4.07 0.25 0
    BRISTOL-MYERS SQUIBB CO BMY 2023-01-27 13:45:03 UTC 4.07 0.25 0
    BRISTOL-MYERS SQUIBB CO BMY 2023-01-27 13:15:03 UTC 4.07 0.25 0
    BRISTOL-MYERS SQUIBB CO BMY 2023-01-27 12:45:03 UTC 4.07 0.25 0

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    FundVantage Trust- Gotham Master Neutral Fund BMY -13.0 shares, $-783.77 2020-09-30 N-PORT
    FundVantage Trust- Gotham Neutral 500 Fund BMY -42.0 shares, $-2651.46 2021-03-31 N-PORT
    American Century Capital Portfolios, Inc.- AC Alternatives Market Neutral Value Fund BMY -5384.0 shares, $-318571.28 2021-09-30 N-PORT
    Weiss Strategic Interval Fund- Weiss Strategic Interval Fund BMY -13266.0 shares, $-943079.94 2022-09-30 N-PORT
    FundVantage Trust- Sirios Long/Short Fund BMY -1835.0 shares, $-130450.15 2022-09-30 N-PORT
    PACE SELECT ADVISORS TRUST- PACE Alternative Strategies Investments BMY -1528.0 shares, $-118374.16 2022-10-31 N-PORT
    Series Portfolios Trust- Weiss Alternative Multi-Strategy Fund BMY -2441.0 shares, $-189104.27 2022-10-31 N-PORT

    Congressional Transactions Past 6-Months

    To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***
    Congress Person Party Chamber Filing Filing Date Transaction Date Security Type Owner Transaction Amount
    Hon. Kurt Schrader democrat House Filing 2022-12-01 2022-11-08 S $1,001-$15,000
    Hon. Kurt Schrader democrat House Filing 2022-12-01 2022-11-08 S $1,001-$15,000
    Hon. Nicholas V. Taylor House Filing 2022-11-28 2022-11-28 SP $100,001-$250,000
    representative Kathy Manning democrat House Filing 2022-08-02 2022-07-15 SP P $1,001-$15,000

    Elevate your investments